Suppliers / Apitoria Pharma

Apitoria Pharma

India 848 employees 2 duplicate records merged Updated 9 July 2026

Apitoria Pharma is an API manufacturer based in India. It holds 303 active US drug master files and 173 valid CEPs. Its GMP standing is certified by US FDA, EMA and MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 12 December 2025 as VAI.

303
active US DMFs
173
valid CEPs
8
registered plants 7 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
7 of 7 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 12 December 2025 VAI US FDA
  • 29 August 2025 VAI US FDA
  • 17 December 2024 VAI US FDA
  • 27 September 2024 VAI US FDA
  • 10 May 2024 VAI US FDA
  • 19 May 2023 VAI US FDA
  • 3 March 2023 VAI US FDA
  • 18 November 2022 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, India Not on file
Srikakulam, India 3004611182
Anakapalli, India 3014477031
Anakapalli, India 3007698192
Sangareddy, India 3006370489
Sangareddy, India 3004051616

2 further sites are on record.

What they file, and where

Molecule Regulators Docs
Ampicillin EDQM, SFDA (Saudi Arabia), US FDA 6
Nevirapine EDQM, US FDA 6
Mirtazapine EDQM, SFDA (Saudi Arabia), US FDA 5
Omeprazole EDQM, US FDA 5
Amoxicillin EDQM, US FDA 4
Clopidogrel EDQM, US FDA 4
Esomeprazole EDQM, US FDA 4
Finasteride EDQM, SFDA (Saudi Arabia), US FDA 4
Fluconazole EDQM, US FDA 4
Lacosamide EDQM, US FDA 4
Show all 30 molecules on file
Lamivudine EDQM, US FDA 4
Olanzapine EDQM, US FDA 4
Olmesartan Medoxomil EDQM 4
Oxacillin EDQM, US FDA 4
Pantoprazole EDQM, US FDA 4
Sulbactam EDQM, US FDA 4
Abacavir EDQM, US FDA 3
Amlodipine EDQM, SFDA (Saudi Arabia), US FDA 3
Aripiprazole EDQM, US FDA 3
Carvedilol EDQM, US FDA 3
Cefixime EDQM, US FDA 3
Cephalexin EDQM, US FDA 3
Citalopram EDQM, US FDA 3
Duloxetine EDQM, US FDA 3
Escitalopram EDQM, US FDA 3
Flucloxacillin EDQM 3
Fluoxetine EDQM, US FDA 3
Gabapentin EDQM, US FDA 3
Hydrochlorothiazide EDQM, US FDA 3
Levetiracetam EDQM, US FDA 3

Also appears on these molecule pages

Show 93 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 5
EMA None 3
MFDS (Korea) None 2

Comparing suppliers?

Choose your molecules and target markets. Apitoria Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 11 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 12 December 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates